Eaton Vance Management’s Aimmune Therapeutics AIMT Stock Holding History

Eaton Vance Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-24,963	Closed	-$860K	–	1473
2020 Q3	$860K	Hold	24,963	–	–	﹤0.01%	1027
2020 Q2	$417K	Hold	24,963	–	–	﹤0.01%	1130
2020 Q1	$360K	Hold	24,963	–	–	﹤0.01%	1115
2019 Q4	$836K	Hold	24,963	–	–	﹤0.01%	1034
2019 Q3	$523K	Hold	24,963	–	–	﹤0.01%	1103
2019 Q2	$520K	Hold	24,963	–	–	﹤0.01%	1096
2019 Q1	$558K	Hold	24,963	–	–	﹤0.01%	1040
2018 Q4	$597K	Hold	24,963	–	–	﹤0.01%	966
2018 Q3	$681K	Hold	24,963	–	–	﹤0.01%	975
2018 Q2	$671K	Hold	24,963	–	–	﹤0.01%	960
2018 Q1	$795K	Hold	24,963	–	–	﹤0.01%	872
2017 Q4	$944K	Hold	24,963	–	–	﹤0.01%	856
2017 Q3	$619K	Hold	24,963	–	–	﹤0.01%	913
2017 Q2	$513K	Hold	24,963	–	–	﹤0.01%	934
2017 Q1	$542K	Buy	+24,963	New	+$512K	﹤0.01%	888

Eaton Vance Management's AIMT Position: Q4 2020 in Review

Eaton Vance Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 24,963 shares — an estimated $860K sold.

Eaton Vance Management first reported a position in AIMT in Q1 2017 and held it in 15 quarters. The position peaked at $944K in Q4 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Eaton Vance Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Eaton Vance Management sold 24,963 Aimmune Therapeutics shares in Q4 2020, an estimated $860K.
Eaton Vance Management first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 15 quarters.
Eaton Vance Management's Aimmune Therapeutics position peaked at $944K in Q4 2017.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Eaton Vance Management's 13F filing for Q4 2020, filed 12 Feb 2021.